Hi Damiamm83,Great question. I can only think that it hadn't...

Hi Damiamm83,

Great question. I can only think that it hadn't been tested on neurodegenerative disorders. We didn't know it crossed the blood brain barrier and affected Neuro filament light assays. ALS MND was an unknown then. PAA didn't have a patent to suit. So no further thought was involved. The main focus back then was a Cancer drug for our four legged friends. I do remember the interested parties on HC who most are still around, which is great , were chatting about dogs and getting that over the line. PAA management tried no doubt. The problem I saw was that the dogs disease is insidious and a quick onset. There seemed to be a time lag in diagnosing and then onto the drug. At the end of the day we came to a standstill. Then out of the blue lead by Dr Mollards idea on ALS MND we were away again. How he came to that great fortune of a thought to contact Fight MND etc I really don't know. If anyone does, I would be happy to place that jig saw piece.

Hi Rodad,

You have brought up another worthy contender. As people know we here at HC critique the other drugs. Two reasons to provide information to ourselves and due to our bias we support the Monepantel derivative and wish ours comes first. Human nature. The unbiased version is probably the best. Let's have a quick look.

1.Probucol is not for ALS.
2. It doesn't affect TDP 43 is the probable answer.
3. May it work on different sub sets of Parkinson's, yes it seems to be working on that pathway.
4. May NUZ-001 work on a different set of pathologic pathways of Parkinson's, yes. Let me try and explain.
5. TDP-43 or similar proteinopathies might be present in 10–20% of PD cases, particularly those with cognitive decline or atypical features. Thus, NUZ-001 as the clearance agent of the proteins responsible for that particular sub set of Parkinson's needs to be elucidated in zebrafish trials to start then we move to rodents then mammals.
6. Probucol may work on the sub sets of Parkinson's that exhibit anti-inflammatory, antioxidant, and vascular-protective degradation maybe 80%.
7. We are looking at Parkinson's as a SoC for sub groups as opposed to blanket penetration of PD.
8. Recent research emphasizes that PD is not a single disease but a spectrum with multiple subtypes, driven by different molecular and pathological processes. However, the classification of these subtypes and their underlying biology is still evolving, and precise, personalized treatment strategies are only beginning to emerge.
9. It's about at this stage we must wait on more data.
10. Probucol is a promising candidate. It's like buying a yearling at the Magic Millions. Someone will win the Melbourne Cup this year!

Kpax